Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prostate-specific antigen (PSA) has been shown to be a more sensitive tumor marker than prostatic acid phosphatase (PAP) in prostatic adenocarcinoma: PSA was positive in 54 of our 117 patients (46%) and PAP was positive in 24 (21%). In order to compare the usefulness of these markers during and after radiotherapy serum samples from 24 patients treated with external beam irradiation were analyzed. PAP was only slightly positive in 1 patient (4%) after radiotherapy. His PSA level was highly elevated and he died of progressive disease. In the other 23 patients the cancer was in local control. However, the serum PSA level remained positive in 5 of these patients indicating vital cancer cells may still have been present. An alternative possibility is that metaplastic prostatic cells which secrete PSA were left after radiotherapy, as has been shown to be the case in prostatic hyperplasia. Before radiotherapy increased PSA levels were measured in 3 patients. In 2 of them the level declined to normal within 6 months after radiotherapy. The PAP levels were normal. It is concluded that PSA (positive in 25% of patients after radiotherapy) might be more sensitive than PAP (positive in 4%) in monitoring the effect of radiotherapy in prostatic cancer patients.
 ...
PMID:Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation. 170 23

Eleven patients with known prostate cancer presented with cranial nerve deficits and skull metastases during the course of their disease. All were treated with radiation therapy to the base of skull. Of the 11 patients, 10 (91%) responded to therapy. Four of the patients in the responder group had complete resolution of the cranial nerve deficits. This response lasted until their death. One patient had a complete response but later relapsed and is still alive. He is the only survivor of the 11 patients. Partial responses were achieved in 5 patients. These patients had either improvement but not resolution of the cranial nerve deficit or, in cases of multiple nerve involvement, there was response of some of the involved nerves. Four of the partial responders retained the response until their death. One patient achieved partial response but later relapsed with additional nerve deficits. The development of this problem represented a grave prognostic factor as 10 patients died within a median of five months (range 1-16 months) after presentation. One patient is alive nineteen months later but in poor condition with disease progression. Only 1 patient (9%) did not achieve any response to therapy. His treatment was not completed due to deterioration of his general health. The seventh cranial nerve was the most frequently involved either alone or in combination with other nerves. The most commonly used treatment schedule was 3,000 rad in 10 treatments (7 cases). We conclude that effective palliation is achieved though short survival is possible.
 ...
PMID:Cranial nerve involvement with carcinoma of prostate. 312 88

A 65-year-old man was hospitalized with bloody sputum. His chest X-ray showed multiple nodules in both lung fields. Transbronchial lung biopsy demonstrated a poorly differentiated adenocarcinoma, which suggested that respiratory abnormalities might be metastatic cancer. Because he had noticed pollakisuria and dysuria, urologic consultation was sought. The findings of digital examination, urethrography, and ultrasonotomography suggested that he had an advanced prostate cancer. In addition, tumor markers of prostatic acid phosphatase (PAP), acid phosphatase (ACP), and prostate antigen (PA) showed abnormal titers; 120 ng/dl, 166 IU/l, and 15.4 ng/ml, respectively. The prostate tissue obtained by transperineal biopsy revealed histopathologically adenocarcinoma and positive findings in immunohistochemical staining for PAP and PA as well as the specimens from the lung. Bilateral orchiectomy and medication of 250 mg of DESD daily as an antiandrogen therapy improved respiratory symptoms. One week after the operation, the multiple shadows on the chest X-ray diminished dramatically. Moreover, serum values of PAP and PA also decreased to the normal range. He is alive in a stable condition 6 months after the operation.
 ...
PMID:[A case of prostate cancer with multiple pulmonary metastases]. 361 15

A 67-year-old man with prostate cancer presented with acute polymyositis and vocal cord paralysis as a result of mediastinal lymphadenopathy. His clinical course was unusual, with the development of a malignant pleural effusion, supraclavicular adenopathy, and osteolytic bone lesions. Urologic symptoms developed only pre-terminally, and osteoblastic bone metastases were not documented. This case suggests that prostate cancer need not have a simple natural history.
 ...
PMID:Prostatic cancer with an unusual presentation: polymyositis and mediastinal adenopathy. 727 58

Susan's father, Sidney Smith, is 63 years old. Recently he has heard on radio and television talk shows that a new test, the Prostate Specific Antigen (PSA), is now available to check for prostate cancer. During his general check-up visit to your office, he mentions this test and wants to know more. He is in excellent health and his urinary review of systems reveals only a slight decrease in the intensity of his urinary stream. On examination he has moderate prostate enlargement but no palpable nodules. His stool test is Hemoccult negative. The remainder of his examination is normal.
 ...
PMID:Screening for prostate cancer. Does it make a difference? 751 44

Prostate-specific antigen (PSA) provides an excellent serum marker for prostate cancer, the most frequent form of cancer in American males. PSA is a 237-residue protease based on sequence homology to kallikrein-like enzymes. To predict the 3-dimensional structure of PSA, homology modeling studies were performed based on sequence and structural alignments with tonin, pancreatic kallikrein, chymotrypsin, and trypsin. The structurally conserved regions of the 4 reference X-ray proteins provided the core structure of PSA, whereas the loop structures were modeled on the loops of tonin and kallikrein. The unique "kallikrein loop" insert, between Ser 95b and Pro 95k of kallikrein, was constructed using molecular mechanics, dynamics, and electrostatics calculations. In the resulting PSA structure, the catalytic triad, involving residues His 57, Asp 102, and Ser 195, and hydrophobic and electrostatic interactions typical of serine proteases were extremely well conserved. Similarly, the 5-disulfide bonds of kallikrein were also conserved in PSA. These results, together with the fact that no major steric clashes arose during the modeling process, provide strong evidence for the validity of the PSA model. Calculation of the electrostatic potential contours of kallikrein and PSA was carried out using the finite difference Poisson-Boltzmann method. The calculations revealed matching areas of negative potential near the catalytic triad, but differences in the positive potential surrounding the active site. The PSA glycosylation site, Asn 61, is fully accessible to the solvent and is enclosed in a positive region of the isopotential map. The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin. This fact, plus other features of the S1 binding-pocket region, suggest that PSA would prefer substrates with hydrophobic residues at the P1 position. The location of a potential zinc ion binding site involving the side chain of histidines 91, 101, and 233 is also suggested. This PSA model should facilitate the understanding and prediction of structural and functional properties of this important cancer marker.
 ...
PMID:A structural model for the prostate disease marker, human prostate-specific antigen. 753 13

A double Malecot-like 16F, polyurethane intraurethral catheter (IUC) was inserted 39 times in 25 patients between 68 and 91 years old (mean +/- SD: 77.5 +/- 5.5 years). Most of them were unfit for surgery because of severe illness or advanced age. All patients except 1 had either an indwelling catheter or a residual urine volume > 50ml at their first visit. The remaining one suffered from prostatic cancer and complained of pollakisuria and urinary incontinence. His symptoms were controlled well after ICU insertion and anticholinergic therapy. Twenty-nine insertions in 17 patients were considered successful, and the patients with successfully inserted stents voided without residual urine. Nine of 21 patients needed to take anticholinergic drugs. The mean duration of IUC use was 113 days in successful cases. In 9 out of 17 patients with an indwelling IUC for more than 112 days, the catheter became blocked by stones or clots. Therefore, we consider that the device should be changed after 110-120 days. Ten insertions failed for the following reasons: malposition, inappropriate IUC length, spontaneous migration to the bladder in patients with a short prostatic urethra, urinary retention due to underactive detrusor, and total incontinence and bleeding from prostatic cancer.
 ...
PMID:[Experience with polyurethane intraurethral stents in aged patients]. 768 14

Thyrotropin-releasing hormone-immunoreactive peptides (iTRH) were analyzed in normal rat and rabbit prostates and in human benign prostatic hyperplasia (BPH) and prostate cancer. Peptides were extracted from tissues, fractionated by anion and cation exchange chromatography, and analyzed by TRH radioimmunoassay. pGlu-Glu-Pro-NH2 predominated in rabbit, but accounted for only 10-15% of iTRH in rat and human BPH. Uncharged peptides predominated in rat and human prostate. Authentic TRH (pGlu-His-Pro-NH2) is not present in rabbit prostate, but may account for up to 25% of iTRH in rat and human prostate. iTRH was virtually absent in prostate cancer. These results demonstrate considerable heterogeneity in the expression of TRH-like peptides in the prostates of various animal species, and suggest decreased expression of these peptides in prostate cancer.
 ...
PMID:Expression of prostatic TRH-like peptides differs between species and between malignant and nonmalignant tissues. 769 Sep 55

A 78-year-old man visited our hospital complaining of pollakisuria, dysuria, and edema of lower extremities. Physical examination revealed a hard, fixed and fist size mass in the abdomen Lymph nodes of left supraclavicular fossa were hardly palpable. His prostate was larger than a hen's egg, stony hard and fixed in the pelvis on digital rectal examination (DRE). The prostate specific antigen (PSA) level was elevated to 584 ng/ml. Computerized tomography (CT) revealed enlarged retroperitoneal lymph nodes. Bone scan showed multiple abnormal uptake. Prostate biopsy showed poorly differentiated adenocarcinoma. Treatment with the LH-RH analogue was very effective. The retroperitoneal lymph nodes were no longer enlarged on CT. The prostate had become soft and was reduced to walnut size on DRE. The PSA level had decreased to within the normal range. The multiple abnormal uptake on the bone scan decreased. This is the 21st case of prostate cancer with large lymph node metastasis in Japan.
 ...
PMID:[Marked effectiveness of the LH-RH analogue in a case of prostate cancer with large lymph node metastasis]. 794 72

The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52-year-old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.
 ...
PMID:Acute renal toxicity associated with suramin in the treatment of prostate cancer. 806 93


1 2 3 4 5 6 7 8 9 10 Next >>